Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients
- PMID: 24706057
- DOI: 10.1007/s11033-014-3339-7
Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients
Abstract
Hepatitis B virus (HBV) cccDNA levels is an absolute marker of HBV replication in the liver of HBV infected patients. This study aimed to quantify the HBV cccDNA levels in sera and liver tissue samples of treatment naïve patients with chronic hepatitis B. Eighty one chronic hepatitis B (CHB) treatment naïve patients were enrolled from January 2009 to June 2011. Total HBV DNA and HBV cccDNA levels were quantified using sensitive real time PCR assay. The mean age of recruited patients was 34 ± 11.5 years. Fifty four (66.7%) patients were HBeAg negative. Liver tissue samples were available from 2 HBeAg positive and 21 HBeAg negative CHB patients. The amount of total intrahepatic HBV DNA ranged from 0.09 to 1508.92 copies/cell. The median intrahepatic HBV cccDNA was 0.31 and 0.20 copies/cell in HBeAg positive and HBeAg negative cases, respectively. Serum HBV cccDNA was detectable in 85.2 % HBeAg positive and 48.1% HBeAg negative CHB patients. Median serum HBV cccDNA was 46,000 and 26,350 copies/mL in HBeAg positive and HBeAg negative subjects, respectively. There was a significant positive correlation between the levels of intrahepatic total HBV DNA and intrahepatic HBV cccDNA (r = 0.533, p = 0.009). A positive correlation was also seen between serum HBV cccDNA levels and serum HBV DNA levels (r = 0.871, p < 0.001). It was concluded that serum HBV cccDNA could be detectable in higher proportion of HBeAg positive patients compared to HBeAg negative patients. Moreover, the median level of serum HBV cccDNA was significantly higher in HBeAg positive patients in contrast to HBeAg negative subjects.
Similar articles
-
Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.Clin Res Hepatol Gastroenterol. 2017 Dec;41(6):635-643. doi: 10.1016/j.clinre.2017.03.004. Epub 2017 Apr 21. Clin Res Hepatol Gastroenterol. 2017. PMID: 28438570
-
Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg.Liver Int. 2024 Oct;44(10):2753-2762. doi: 10.1111/liv.16032. Epub 2024 Jul 29. Liver Int. 2024. PMID: 39073214
-
Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection.PLoS One. 2014 Feb 13;9(2):e89046. doi: 10.1371/journal.pone.0089046. eCollection 2014. PLoS One. 2014. PMID: 24551214 Free PMC article.
-
Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Aliment Pharmacol Ther. 2018 Jan;47(1):43-54. doi: 10.1111/apt.14376. Epub 2017 Oct 16. Aliment Pharmacol Ther. 2018. PMID: 29035003 Review.
-
HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History.Viruses. 2022 Jul 30;14(8):1691. doi: 10.3390/v14081691. Viruses. 2022. PMID: 36016312 Free PMC article. Review.
Cited by
-
Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B.Hepat Mon. 2015 Sep 29;15(9):e30790. doi: 10.5812/hepatmon.30790. eCollection 2015 Sep. Hepat Mon. 2015. PMID: 26504471 Free PMC article.
-
Detection of HBV Covalently Closed Circular DNA.Viruses. 2017 Jun 6;9(6):139. doi: 10.3390/v9060139. Viruses. 2017. PMID: 28587292 Free PMC article. Review.
-
Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii.Int J Nanomedicine. 2015 Oct 8;10:6355-69. doi: 10.2147/IJN.S85286. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26504384 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical